Advertisement
Embase has long played a key role in the advancement of new biomedicaland pharmaceutical insights. Now, new developments and updates include:
Thomas Gutjahr, Head of the Knowledge Center at Actelion PharmaceuticalsLtd., comments: "I'm very impressed by all the new improvements which Ibelieve will greatly help with pin-pointing certain searches, e.g. drug-druginteractions or drug-disease searches."
Advertisement
Embase supports researchers with key tasks such as tracking of drugadverse events, comparing drug therapies, and Evidence Based Medicineresearch. It provides researchers with deep insights and understanding fromthe world's life sciences information, enabling effective discoveries towardsmedical discovery and treatment.
ABOUT ELSEVIER
Elsevier is a world-leading publisher of scientific, technical andmedical information products and services. The company works in partnershipwith the global science and health communities to publish more than 2,000journals, including The Lancet (http://www.thelancet.com) and Cell(http://www.cell.com), and close to 20,000 book titles, including majorreference works from Mosby and Saunders. Elsevier's online solutions includeScienceDirect (http://www.sciencedirect.com), Scopus (http://www.scopus.com),Reaxys (http://www.reaxys.com), MD Consult (http://www.mdconsult.com) andNursing Consult (http://www.nursingconsult.com), which enhance theproductivity of science and health professionals, and the SciVal suite(http://www.scival.com) and MEDai's Pinpoint Review (http://www.medai.com),which help research and health care institutions deliver better outcomes morecost-effectively.
A global business headquartered in Amsterdam, Elsevier (http://www.elsevier.com) employs 7,000 people worldwide. The company is partof Reed Elsevier Group PLC (http://www.reedelsevier.com), a world-leadingpublisher and information provider, which is jointly owned by Reed ElsevierPLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam),REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).- Enabling all biomedical researchers to use Embase -- extending its "usability" from information specialists to also include all biomedical and pharmaceutical scientists, and clinical and regulatory professionals. - New retrieval tools that further drive discovery, including quick and easy refining of search results and the display of indexed drug-drug and drug-disease relations. - Improved comprehensiveness through the addition of indexed articles-in-press and conference abstracts. - To signify the enhanced focus on biomedical answers, the product has a new, fresh look and feel to it.
SOURCE Elsevier
